RWA EVENT INTELLIGENCE

Trace the record, identity, and observed market reaction.

One source-backed desk for dated events and standing references, mapped to exact XRPL currency-plus-issuer identities without confusing underlying-company news with token-issuer activity.

Open briefing Source network

Dated source records48/48 exact identities68 source-dated eventsNo inferred timestamps

Accepted records: 121
Dated events: 68
Standing references: 53
Exact identities: 48
Source channels: 30
Protocol records: 2

Event and reference registry121 of 121

Source: Eli Lilly Investor Relations
Temporal state: Source-dated event
Identity scope: One exact market
Market desks: Equities

Before event: —
First after: —
Immediate move: —
Window move: —

Loading accepted market observations

Evidence fieldsLiteral checks

Source transportHTTPS verified

https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-mounjaro-tirzepatide-reduce-cardiovascular

Official labelExplicit

Eli Lilly Investor Relations

Publication timeSource-dated

2026-08-28T11:00:00.000Z

XRPL scope1 exact identity

Currency and issuer mapping present

Exact identity ledger1

wLLY774C4C5900000000000000000000000000000000rwhCoTx1...k99PnDv

Source-dated timeline68 events

Evidence-role distribution121 accepted

Event Intelligence reports only accepted source records and observed market data. It does not infer publication dates, issuer endorsements, causation, or transaction outcomes.

Trace the record, identity, and observed market reaction.

FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes

wLLY exact XRPL path